Lipella Pharmaceuticals Inc. (LIPO)

Market Cap	646.46K -90.2%
Revenue (ttm)	389.78K -19.4%
Net Income	-5.33M
EPS	-1.76
Shares Out	4.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,853
Average Volume	41,094
Open	0.1699
Previous Close	0.1700
Day's Range	0.1000 - 0.1699
52-Week Range	0.0197 - 3.1700
Beta	0.84
RSI	63.49
Earnings Date	May 22, 2026

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: LIPO

Financial Performance

In 2024, Lipella Pharmaceuticals's revenue was $536,357, an increase of 19.29% compared to the previous year's $449,617. Losses were -$5.02 million, 8.60% more than in 2023.